Cagrilintide Tolerability Assessed in Overweight/Obese Individuals Intolerant to GLP-1 Receptor Agonists

Global health faces significant challenges from obesity and overweight, often managed with lifestyle changes and pharmacotherapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven highly effective for weight management and type 2 diabetes. However, many patients experience gastrointestinal (GI) adverse events like nausea, vomiting, and diarrhea, leading to treatment discontinuation. This creates a critical unmet need for alternative or complementary therapies offering comparable efficacy with improved tolerability for those who cannot sustain GLP-1 RA treatment. Cagrilintide, an amylin analog, is being investigated to address this tolerability gap.

This randomized, placebo-controlled clinical study aims to evaluate the safety and tolerability of Cagrilintide in participants with overweight or obesity who previously discontinued GLP-1 RA therapies due to GI adverse events. Participants will be randomly assigned to receive either Cagrilintide or a placebo. The study duration is approximately 8 months. The primary endpoint focuses on the tolerability profile of Cagrilintide compared to placebo in this specific patient population. Specific doses, routes, or frequencies of Cagrilintide were not detailed in the provided abstract, but the design indicates a direct comparison to a control arm.